citalopram / Generic mfg. - LARVOL DELTA

Genotoxicity and DNA Damage in Long-Term SSRI Therapy: A Review Across SSRIs With Citalopram as a Case Study. (PubMed, J Appl Toxicol) - "Comparative findings indicate that citalopram and fluoxetine show the most consistent experimental genotoxic signals, whereas paroxetine and escitalopram are less frequently implicated. Environmental studies raise concern for aquatic organisms. Overall, citalopram shows genuine experimental genotoxic potential, but clinical relevance in humans remains uncertain and warrants robust longitudinal investigation and careful risk-benefit assessment in practice."

Journal • Review • CNS Disorders • Metabolic Disorders • Mood Disorders • Psychiatry

Pharmaceutical footprint in the river ecosystem: suspect screening approach with high resolution mass spectrometry. (PubMed, Environ Pollut) - "Solid matrices such as sediments and sludge accumulated highly hydrophobic substances (e.g., telmisartan, citalopram), whereas aqueous matrices contained more polar compounds (e.g., tramadol) and metabolites. Overall, this study provides one of the most comprehensive multi matrix suspect screening assessments of PhACs to date. The holistic evaluation of the riverine ecosystem highlights the value of HRMS based workflows for identifying and prioritizing emerging contaminants, supporting the development of regulatory strategies to control pharmaceutical pollution and enabling early detection of newly marketed drugs."

Journal • Cardiovascular • Pain

Citalopram and the Risk of Serious Adverse Events (clinicaltrials.gov) - P=N/A | N=7110 | Completed | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Adverse events • New trial • Serious adverse event • Chronic Kidney Disease • Nephrology • Renal Disease

NEONATAL RESPIRATORY DISTRESS FOLLOWING SSRI EXPOSURE: BEYOND PREMATURITY AND ACROSS AGENTS (WRMC 2026) - "By agent, RDS occurred in 41.5% of sertraline, 65.2% of escitalopram, 52.6% of fluoxetine, and 80% of citalopram-exposed infants. In this cohort, one-third of SSRI-exposed neonates with respiratory distress had RDS, extending beyond prematurity into late-preterm and term infants, with mostly non-invasive courses. Escitalopram, and possibly citalopram, carried higher risk than sertraline, suggesting agent-specific differences. Limitations include retrospective single-center design, radiographic interpretation, lack of a control group, and small sample sizes."

Prematurity • Acute Respiratory Distress Syndrome • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data. (PubMed, J Affect Disord) - "This FAERS analysis detected significant disproportionality signals for male sexual dysfunction across SSRIs. Signal variation reflects reporting differences, not comparative risk, due to database limitations. These findings highlight the need for clinical vigilance and further investigation."

Adverse events • Journal • CNS Disorders • Depression • Erectile Dysfunction • Psychiatry • Sexual Disorders

Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs. (PubMed, Elife) - "C5aR1 deficiency or depletion of CD8+ T cells hinders the anti-HCC effects of citalopram. Collectively, our study reveals the immunomodulatory roles of citalopram in inducing anti-tumor immunity and provides a basis for considering the repurposing of SSRIs as promising anticancer agents for HCC treatment."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • CD8

Tracking Metabolic Responses to Citalopram in Colon Cells with Raman Spectroscopy. (PubMed, Anal Chem) - "Citalopram also significantly reduced endoplasmic reticulum and lipid droplet areas in Caco-2 and LoVo cells, indicating disrupted cellular homeostasis and increased sensitivity to toxin-induced stress. In contrast, normal CCD-18Co fibroblasts showed increased lipid droplet accumulation, suggesting an adaptive detoxification response."

Journal • Oncology

Phosphated maltodextrin as an anionic chiral selector for capillary electrophoresis: Application to the enantiomeric separation of basic drugs. (PubMed, J Chromatogr A) - "Its chiral recognition capability in CE was systematically assessed using five model drugs: tramadol, citalopram, hydroxyzine, amlodipine, and fluoxetine. PMD is a new anionic chiral selector combining affordability, solubility, and enhanced selectivity. Major resolution gains without longer analysis times demonstrate PMD's promising potential for routine pharmaceutical applications, with broader chiral separations to be explored in future studies."

Journal

Temporal Patterns of Adverse Events Associated With Selective Serotonin Reuptake Inhibitors: A Global Pharmacovigilance Analysis of Early-Onset Versus Late-Onset Toxicity. (PubMed, Cureus) - "Objective This study aims to explore the timing of AEs associated with six commonly used SSRIs: sertraline, fluoxetine, fluvoxamine, paroxetine, citalopram, and escitalopram using global pharmacovigilance data, with a focus on early- versus late-onset profiles. Early-onset symptoms require timely management to improve tolerability, while late-onset effects highlight the need for ongoing monitoring. These findings can inform personalized monitoring strategies and guide patient counseling to support safer long-term SSRI use."

Adverse events • Journal • CNS Disorders • Dermatology • Diabetes • Insomnia • Metabolic Disorders • Osteoporosis • Rheumatology • Sexual Disorders • Sleep Disorder

Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults. (PubMed, Clin Pharmacol Ther) - "For morphine with CBD for 9 days compared to morphine alone, the GMR for AUC0-inf and Cmax was 1.12 (1.00-1.26) and 1.11 (0.94-1.30), respectively. While a significant pharmacokinetic interaction between CBD and citalopram was observed, interactions between CBD and morphine, as well as its metabolites, were limited."

Journal

A Study on Brain Imaging and Blood Biomarkers of Non-invasive Neuromodulation Therapy for Depression Patients (ChiCTR) - P=N/A | N=120 | Recruiting | Sponsor: The Affiliated Kangning Hospital of Wenzhou Medical University; The Affiliated Kangning Hospital of Wenzhou Medical University

New trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Citalopram treatment window Study Based on PK-PD Model: Correlation analysis of therapeutic drug Monitoring and clinical outcomes in Patients with sleep Disorders and Depression (ChiCTR) - P=N/A | N=200 | Not yet recruiting | Sponsor: Shanghai General Hospital; Shanghai General Hospital

New trial • CNS Disorders • Depression • Mood Disorders • Psychiatry • Sleep Disorder

Efficacy of Acupuncture for Mild to Moderate Depression in Older People: Protocol for a Randomized Controlled Trial. (PubMed, JMIR Res Protoc) - "This randomized controlled trial aims to assess the effects of acupuncture combined with citalopram hydrobromide on mild to moderate depression in older people...This pilot study is expected to provide critical insights into the feasibility of integrating acupuncture with standard medication for managing mild to moderate depression in older people. By generating preliminary evidence on its potential benefits, the study aims to inform the design and sample size estimation of future multicenter trials, potentially advancing nonpharmacological treatment options for depression."

Clinical protocol • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Prefrontal cortex-extracellular vesicle RNAs coupling in alcohol use disorder: towards non-invasive biomarkers and targeted therapeutics. (PubMed, Artif Cells Nanomed Biotechnol) - "Computational drug repurposing identified loratadine, doxepin, citalopram and imipramine as promising therapeutic candidates targeting SERPINA3. Collectively, this work delineated PFC signature genes, proposed a EVs-supported brain-periphery molecular crosstalk, and provided translatable biomarkers and repurposable candidates for AUD precision medicine."

Biomarker • Journal • Addiction (Opioid and Alcohol) • IL17A • SERPINA3

Exploring the effects of pharmacological treatments on suicidality in children and adolescents: a structured review of the literature and narrative synthesis. (PubMed, EClinicalMedicine) - "Esketamine (four studies, n = 211) and ketamine (four, n = 6) use in major depressive disorder induced rapid reduction of acute suicidality within 24 h. In the longer term, lithium (three, n = 923) was beneficial in reducing suicidality in youths with bipolar disorder. Sertraline, citalopram, escitalopram, fluoxetine and duloxetine (six, n = 906) yielded inconsistent results. Other agents, including valproate, lamotrigine and antipsychotics such as clozapine and quetiapine exhibited some benefit in reducing suicidality, but findings were limited to small-scale studies...Further high-quality studies investigating suicidal thoughts and behaviours as independent treatment targets are needed to guide clinical decision-making. None."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Psychiatry • Suicidal Ideation

The menopause after cancer study: A multimodal technology assisted intervention for the management of menopausal symptoms after cancer. (ASCO 2023) - P2 | "The intervention consisted of: (1) use of non-hormonal pharmacotherapy to manage VMS (citalopram for predominantly daytime VMS and/or gabapentin for predominantly nocturnal VMS) (2) digital cognitive behavioural therapy for insomnia using Sleepio (BigHealth), (3) self-management strategies for VMS delivered via a mobile application called myPatientSpace and (4) nomination of an additional support person/partner. The MAC study demonstrates that improvements in QoL can be achieved using this multimodal intervention to target VMS and insomnia after cancer. Clinical trial information: NCT04766229."

Breast Cancer • CNS Disorders • Insomnia • Oncology • Sleep Disorder • Solid Tumor

Effect of antidepressants on motor and functional recovery in stroke: a systematic review and meta-analysis. (PubMed, BMC Neurol) - "Certain antidepressants may enhance motor performance and independence in performing activities of daily living during post-stroke recovery among elderly patients. Fluoxetine was the most common antidepressant described in the literature with significant improvement in motor (FMMS) functional (BI) scales. However, substantial heterogeneity and potential study biases warrant cautious interpretation. Rigorous, large-scale RCTs are necessary to verify these findings and establish long-term safety profiles. They will also help define the optimal therapeutic strategies before routine clinical use is considered."

Journal • Retrospective data • Cardiovascular

Pharmacological management of agitation in dementia: An evidence-based review with expert consensus. (PubMed, J Chin Med Assoc) - "Among the approved agents, brexpiprazole demonstrated the strongest evidence and most favorable safety profile. Risperidone and aripiprazole are effective, but require careful monitoring for cerebrovascular and extrapyramidal risks. Selected antidepressants, particularly citalopram and agomelatine, should be considered when safety is prioritized. Anticonvulsants, acetylcholinesterase inhibitors, and memantine have limited efficacy and should be reserved for refractory cases. Long-term or routine pharmacological use is not supported by current evidence. Future research should focus on identifying responsive patient subgroups, optimizing dosing strategies, and integrating medications into individualized, multidisciplinary care plans."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Psychiatry

Comparative Real-World Safety Profiles of Six Selective Serotonin Reuptake Inhibitors: A Global Pharmacovigilance Analysis. (PubMed, Cureus) - "Methods We conducted a comprehensive pharmacovigilance analysis utilizing VigiBase, the WHO global database of individual case safety reports, encompassing over 342,000 reports for six major SSRIs (sertraline, fluoxetine, paroxetine, citalopram, escitalopram, and fluvoxamine). Conclusions This analysis reveals that SSRIs exhibit distinct safety profiles that correlate with their pharmacodynamic properties, challenging the traditional view of these medications as a homogeneous therapeutic class. These findings support precision prescribing approaches based on individual patient risk factors and provide mechanistic insights for evidence-based SSRI selection."

Adverse events • Journal • Real-world evidence • CNS Disorders • Sexual Disorders • Sleep Disorder

Risk of gastrointestinal bleeding by specific SSRIs and SNRIs: A systematic review and meta-analysis. (PubMed, Br J Clin Pharmacol) - "GIB is an uncommon adverse event, but this analysis demonstrates that the risk of GIB is elevated for commonly used SSRI/SNRI products, highlighting the relevance for those patients with an increased risk of GIB."

Journal • Retrospective data • Review • Gastroenterology

Rising Escitalopram Use in British Columbia: Is it Rational and Evidence-Informed? (PubMed, Can J Psychiatry) - "Plain Language Summary TitleCitalopram vs. Escitalopram for major depression: No Real Difference in Efficacy or Safety, Just Higher Cost.Plain Language SummaryBackground:Citalopram is an antidepressant. Claims that escitalopram works faster were weak and inconsistent. Side effects were essentially the same, including risks for heart rhythm changes (QT prolongation)."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Psychiatry

Drug Development. (PubMed, Alzheimers Dement) - "Pharmacological management should be individualized, considering symptoms, comorbidities, and frailty. Medications should be used at the lowest effective dose and for the shortest possible duration to minimize side effects."

Journal • Review • Alzheimer's Disease • Anesthesia • CNS Disorders • Dementia • Movement Disorders • Pain • Parkinson's Disease • Psychiatry

Examining pharmacological and demographic factors among male and female alzheimer's disease patients diagnosed with attention concentration disorder and cognitive communication disorder. (PubMed, Geriatr Nurs) - "These results underscore the urgent need to establish strategies aimed at addressing sex disparities in the care of ADACD and ADCCD patients."

Journal • Alzheimer's Disease • CNS Disorders • Developmental Disorders

Dementia Care Research and Psychosocial Factors. (PubMed, Alzheimers Dement) - "There is considerable variability in AAD-related treatment approaches among Canadian clinicians. Our findings highlight the need for more evidence on treatments specifically indicated for AAD, and education to facilitate evidence-based clinical practice."

Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Dementia

Stable remission of depression after antidepressant treatment: prevalence and related sociodemographic and clinical characteristics in a longitudinal, real-world cohort. (PubMed, J Affect Disord) - "Nearly half of patients starting antidepressant medication reached stable remission. Higher depressive symptoms and higher dose - both likely reflecting more severe depression - were associated with lower remission rates. Findings highlight the need to identify and address factors hindering stable remission."

Journal • Real-world evidence • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry